December 7, 2021 | 11:00 am – 3:00 pm EST | Free online program
Biomarker testing, when used appropriately, allows the cancer care team to more effectively select treatment or risk reducing interventions for patients, while improving survival outcomes and reducing adverse effects. Unfortunately, effective use
of and access to biomarker testing is still highly dependent on health care coverage; patient and provider education; and patient geographic location and socioeconomic status. The NCCN Patient Advocacy Summit will provide an opportunity for a varied
group of stakeholders including patients, providers, payers, patient advocacy organizations, and industry to thoughtfully discuss the importance of providing quality, accessible, and equitable cancer care to patients in need of biomarker testing and
Supported by AbbVie, Adaptive, ADC Therapeutics, AmerisourceBergen, Apobiologix, Astellas, AstraZeneca, BeiGene, bluebird bio, BMS, Boehringer Ingelheim, Eisai, EMD Serono, EQRx, Exact Sciences, Exelixis, Foundation Medicine, GSK, Helsinn, Heron, Incyte, Janssen, Kite Pharma, Lilly, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, QED Therapeutics, Regeneron, Sanofi, Servier, Sun Pharma, Taiho, and TG Therapeutics.